K&L Gates LLP
Rho kinase inhibitors
Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
Aerie Pharmaceuticals, Inc.
A A C A C C C C C C A A A C A C C A
A61K A61P C07D A61K C07D C07D C07D C07D C07D C07D A61P A61K A61K C07D A61K C07D C07D A61K
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Erick Richard Thomas Martin Cheng-Kon Anthony S. John David Weimin Sabine K. Michael Robert Todd Roger John Frank Eugene Richard
Young Kirrane, Jr. Shih Prokopowicz Ginn Liu Schlyer Turner Bosanac Snow Wu Hickey